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Abstract 
Introduction: Exaggerated activation of lymphocytes contributes to the pathogenesis 
of inflammatory bowel disease (IBD). Medical therapies are linked to the BCL-2 
family-mediated apoptosis. Imbalance in BCL-2 family proteins may cause failure in 
therapeutic responses. We investigated the role of BCL-2 inhibitor ABT-737 for 
lymphocyte apoptosis in mice under inflammatory conditions. 
Methods: B.6129P2-Il10tm1Cgn/J (IL-10-/-) weighing 25-30 g with ongoing colitis were 
used. 50 mg/kg/day ABT-737 was injected i.p. Hematological analyses were 
performed with an ADVIA 2120 flow cytometer and mass cytometry with a CyTOF 2. 
Results: Following i.p. administration ABT-737 was detected in both spontaneous 
and acute colitis in peripheral blood (PBL) and colon tissue. Treatment lead to 
lymphopenia. CD4+ CD44+ CD62L+ central memory and CD8+, CD44+ CD62L- 
central memory T cells were decreased in PBL upon ABT-737 compared to vehicle-
receiving controls. Increased apoptosis upon ABT-737 was determined in blood 
lymphocytes, splenocytes and Peyer’s patches and was accompanied by a decrease 
in TNF and IL-1B. ABT-737 positively altered the colonic mucosa and ameliorated 
inflammation as shown by colonoscopy, histology and colon length. A decreased BIM 
/ BCL-2 ratio or absence of BIM in both Bim-/- and Il10-/- x Bim-/- impeded the 
protective effect of ABT-737. BIM / BCL-2 ratio was decreased with age and over the 
course of treatment. Thus long-term treatment resulted in adapted TNF levels and 
macroscopic mucosal damage. 
Discussion: ABT-737 was efficacious in diminishing lymphocytes and ameliorating 
colitis in a BIM dependent manner. To regulate inappropriate survival of lymphocytes 
by ABT-737 may provide a therapeutic strategy in IBD.  
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INTRODUCTION 
 
The BCL-2 family plays a critical role in controlling immune responses by regulating 
the expansion and contraction of the activated lymphocyte population via apoptosis. 
The majority of activated T cells die at the end of a T cell response, which coincides 
with the exhibition of decreased levels of BCL-2 just before they begin to die in vivo 
(1). A decrease of the pro-survival BCL-2 contributes to apoptosis of activated T cells 
(2). In patients suffering from IBD, the lifespan of antigen-primed and activated T 
cells is extended and an abnormal population of activated T cells is retained within 
the mucosal compartment (3-5). Enhanced expression of anti-apoptotic BCL-2 is 
found in lamina propria lymphocytes from inflamed CD tissue after CD2 pathway 
stimulation (3). Elevated BCL-2 level is also found in cultures of unstimulated T cells 
isolated from inflamed CD tissue (3). Lamina propria T cells in CD show an activation 
of the STAT-3 signalling pathway in response to IL-6. STAT-3 mediates the 
expression of anti-apoptotic genes such as BCL-2 and BCL-XL (6). Resistance of CD 
T cells to apoptotic signals is correlated with an increased BCL-2 expression (3). This 
is further supported by reports of a higher BCL-2/BAX ratio in CD mucosa compared 
to controls (4) as well as a resistance to Fas-induced apoptosis in peripheral T cells 
acquired from CD patients (7). Apoptosis of anti-inflammatory regulatory T cells (Treg 
cells) is reduced in both mucosal and peripheral CD4+CD25highFoxp3+ Treg cells of 
IBD patients (8).  
Anti-apoptotic BCL-2 interacts with the pro-apoptotic BH3-only protein family member 
BIM to regulate the survival of lymphocytes. The summary effect of the interaction 
between BCL-2 and BIM is dependent on the cell type but is also tissue specific, 
whereby BCL-2 promotes the survival of naïve T cells (9). Indeed, naïve T cells from 
Bim+/- Bcl-2-/- mice die at an accelerated rate in vitro. BCL-2 is critical in preventing 
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the pro-apoptotic effects of BIM in naïve CD8+ T cells in vivo, but molecules other 
than BCL-2 may antagonize BIM in CD4+ cells. BIM controls T cell numbers in the 
periphery by promoting apoptosis and/or decreasing their thymic production. Bim-
deficient mice have elevated numbers of normal single positive T cells in the 
periphery (10). Furthermore, BIM is a primary trigger for killing B-cells during their 
development (11). Bim deficiency prevents the death of activated T cells in vitro and 
in vivo, suggesting that the protective effect of BCL-2 is mediated solely by 
neutralization of BIM (2).  
Inflammatory bowel disease (IBD) affects about one in a hundred and fifty people in 
the industrialized world. IBD is characterized by a chronic inflammation of the 
intestinal wall and comprises two main conditions, namely ulcerative colitis (UC) and 
Crohn’s disease (CD). In the pathogenesis of IBD this inflammatory state is sustained 
by an exaggerated response of T-lymphocytes to luminal antigens associated with an 
increased resistance to the induction of apoptosis (4).  
Central elements of medical therapy consist of sulfasalazine, aminosalicylates, 
steroids, immunomodulators and biologicals (12, 13). Medical therapies that regulate 
lymphocyte proliferation and contraction are directly linked to the BCL-2 family-
mediated apoptosis. Sulfasalazine is a potent pro-apoptotic agent (14) as confirmed 
in peripheral blood lymphocytes from CD patients and in lamina propria T-
lymphocytes isolated from inflammatory lesions in CD patients. Induction of 
apoptosis by sulfasalazine is associated with a decrease in anti-apoptotic BCL-XL 
and BCL-2. Glucocorticoids inhibit the synthesis of IL-1 and IL-2, resulting in the 
suppression of the T cell-dependent immune reaction and T cell proliferation (15). 
Azathioprine (AZA) is an immunosuppressive agent which interferes with T cell-
proliferation via its metabolite 6-thioguaninnucleotide. AZA therapy reduces natural 
killer cells in blood and lamina propria by increasing apoptosis (16). Increased early 
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and late apoptosis upon AZA was determined in CD4+ T cells from peripheral blood 
isolated from control patients but not from CD patients (17). BCL-XL is suppressed 
by AZA, therefore leading to apoptosis through a mitochondrial pathway (18). Anti-
TNF antibodies are used in CD and UC to induce and maintain remission. Infliximab 
was shown to induce apoptosis and an increase in the Bax/Bcl-2 ratio of CD3/CD28 
stimulated Jurkat T cells (19). Furthermore the activation of BAX and BAK triggers 
apoptosis in lamina propria lymphocytes and monocytes by activating the caspase 
family and inducing cytochrome c release (20). Administration of all clinically effective 
anti-TNF antibodies resulted in a significant induction of T cell apoptosis in IBD when 
lamina propria CD4+ T cells expressing TNFR2+ were co-cultured with mTNF+ CD14+ 
intestinal macrophages (21).  
Boosting the initiation of cell death in apoptosis-resistant lymphocytes could improve 
the success of medical therapy. ABT-737 (AbbVie) is a potent inhibitor of BCL-2, 
BCL-XL, BCL-W (22, 23) and has been shown to disrupt the interactions of BCL-2 
family proteins to induce apoptosis in cancer. ABT-737 inhibits BCL-2 by directly 
blocking BIM-binding sites and displacing BIM, which becomes freely available to 
interact with other BCL-2 molecules in the cell. Additionally BIM can bind to BAX and 
BAK to trigger apoptosis by initiating the formation of pores on the mitochondrial 
surface. ABT-737 is a BH3-only mimetic that shows a potent action against various 
transformed cells while exhibiting minimal toxicity toward normal cells. ABT-737 is 
effective in treating animal models of autoimmune diseases (24), arthritis (25) and 
lupus (26). Furthermore, expression of BIM, and the extent of its association with 
BCL-2, correlates with in vivo ABT-737 sensitivity (27).  
Own studies on apoptosis of lymphocytes in the intestinal mucosa revealed that cell 
death in Peyer’s patches is dependent on the pro-apoptotic protein BIM (28). Based 
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on these findings we investigated the role of ABT-737 in the cell death of 
lymphocytes in mice under inflammatory conditions.  
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MATERIALS AND METHODS 
 
Ethical Considerations 
The experimental protocol was approved by the local Animal Care Committee of the 
University of Zurich (Cantonal Ethics Committee of Zurich, 162/2011).  
 
ABT-737 treatment 
ABT-737 was provided by AbbVie Bioresearch (USA) and was injected intra-
peritoneally (i.p.) at a dose of 50 mg/kg/day. The vehicle consisted of polyethylene 
glycol, Tween 80, dextrose solution and DMSO. 
 
Murine colitis models 
Acute dextran sulfate sodium (DSS)-induced colitis: B6.129-Bcl2l11tm1.1Ast/J (Bim–
/–) mice were kindly provided by Professor Dr Andreas Villunger (Division for 
Developmental Immunology, Innsbruck Medical University). Bim–/– mice were back-
crossed for at least 12 generations. Acute colitis was induced in female C57-BL/6J-
Fue and Bim-/- mice by administration of 2 % DSS over nine days. Mice weighing 20-
25 g were used for the experiments and housed in individually ventilated cages 
(IVC). All animals were housed for at least three weeks prior to testing in a specific 
pathogen free (SPF) facility. Animals were sacrificed on day nine. Acute DSS-
induced colitis is an animal model for acute intestinal barrier disturbance and acute 
damage. 
Spontaneous colitis: B.6129P2-Il10tm1Cgn/J (Il10-/-, mice were ordered from The 
Jackson Laboratory and were already backcrossed to the C57BL/6J genetic 
background for several generations) and B.6129P2-Il10tm1Cgn/J x B6.129-
Bcl2l11tm1.1Ast/J (Il10-/- x Bim-/-) develop colitis after 12-15 weeks under SPF 
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conditions. Il10-/- weighing 25-30 g were used for the experiments. Animals were 
sacrificed on day 14 of ABT-737 treatment. The Il10-/- model of colitis reflects the 
exaggerated immune reaction against the endogenous gut flora as seen in CD 
patients. Il10-/- have a low penetrance of disease when raised under SPF conditions, 
and therapeutic studies in this model are difficult to perform. Therefore we defined a 
clearly visible rectal prolapse as external visible indicator of ongoing colitis in our Il10-
/- colony as also stated in the results section whenever Il10-/- suffering from ongoing 
colitis were used. 
 
Assessment of colonoscopy and histological score in mice 
Animals were anesthetized with isoflurane and examined with the Tele Pack Pal 
20043020 (Karl Storz Endoskope, Germany) and scored according to the murine 
endoscopic index of colitis severity (MEICS) as previously described (29). For the 
assessment of the histological scores, 1 cm of the distal third of the colon was 
removed and scored as described (30, 31).  
 
Cell isolation 
Murine peripheral blood lymphocytes were used for mass cytometric analyses. 
Whole blood was collected in EDTA-treated collection tubes (BD vacutainer, REF 
367525). ACK (1,5M NH4Cl, 100mM KHCO3, 10mM Triplex111, ph 7.2) lysing buffer 
was used for lysing red blood cells.  
Splenocytes were isolated using the gentleMACS octo dissociator (Miltenyi, #130-
095-937) and gentleMACS C tubes (Miltenyi, #130-093-237). One mouse spleen was 
transferred into a gentleMACS C tube containing 10ml ACK. A single-cell suspension 
was obtained by using the gentleMACS octo dissociator program m_spleen 03 for 
three times. Splenocytes were passed over a 70 μm mesh filter and centrifuged. 
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Cells were resuspended in 1ml ACK, centrifuged, resuspended in PBS and passed 
over a 70 μm mesh filter again to obtain 200 – 300 x 106 splenocytes/spleen. 
Lamina propria mononuclear cells (LPMNC) from small bowel were isolated with the 
help of the lamina propria dissociation kit (Miltenyi, #130-097-410) according to the 
manufacturer’s protocol. 
 
Mass cytometry, staining, data acquisition and analysis 
Single cell suspensions obtained from peripheral blood, spleen and lamina propria 
were stained according to the manufacturer's recommendations (MaxPar Cell 
Surface Staining Protocol and MaxPar Cytoplasmic/Secreted Antigen Staining 
Protocol). In short, for viability staining cells were washed with PBS and resuspended 
in PBS to a maximum concentration of 1x107/mL. Cell-ID Cisplatin reagent (Fluidigm, 
cat. no. 201064) was added to a final concentration of 5 µM. Following 5 minutes 
incubation at room temperature, samples were washed with cell staining buffer 
(Fluidigm, cat. no. 201068) by adding 5X the volume of the initial cell suspension. 
Each sample was resuspended in a volume of 50 µL of cell staining buffer and 50 µL 
of the surface antibody cocktail was added (MaxPar Mouse Spleen/Lymph Node 
Phenotyping Panel Kit, cat. no. 201306). Following 30 minutes incubation at room 
temperature, samples were washed twice with 2mL of cell staining buffer each and 
fixed by adding 1 mL of 1X MaxPar Fix I Buffer (Fluidigm, cat. no. 201065) to each 
tube, gently vortexed and incubated at room temperature for additional 15 minutes. 
Cells were washed twice with 2 mL of MaxPar Perm-S buffer each (Fluidigm, cat. no. 
201066) and resuspended in 50 µL of the same buffer. The intracellular antibody 
cocktail (MaxPar Mouse Intracellular Cytokine I Panel Kit, cat. no. 201310) was 
added to each sample in 50uL volume and incubated for 30 minutes at room 
temperature. Following two washing steps with 2 mL of cell staining buffer each, cells 
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were labeled with 1 mL of 100 nM iridium intercalation solution (Fluidigm, cat. no. 
201192B) in MaxPar Fix and Perm buffer (Fluidigm, cat. no. 201067) at 4 °C 
overnight. Cells were washed twice with 2 mL cell staining buffer each and once with 
water (Merck Milipore Ultrapure Mili-Q water, 18.2 MΩ*cm@25°C). Cells were left 
pelleted until ready for acquisition, at which point their concentration was adjusted to 
1-1.5 x 106 cells/mL in the Ultrapure Mili-Q water. 
Cells were acquired on the CyTOF 2 instrument (Fluidigm, USA) with an acquisition 
flow rate of 0.045mL/min and following data processing settings (default thresholding 
scheme, lower convolution threshold of 200 IU, minimum event duration of 12 
pushes, maximum event duration of 100 pushes, noise reduction active). All samples 
were spiked with EQ four element calibration beads during acquisition (Fluidigm, cat. 
no. 201078) and resulting FCS files were normalized according to the built-in 
normalization algorithm (CyTOF software version 6.0.626) to account for intra- and 
inter-sample intensity measurement variability. Resulting data was analyzed with 
FlowJo (Flowjo LLC, USA) and Cytobank (Cytobank Inc, USA) software. 
 
Blood analyses 
Hematological analyses were performed by the Division of Hematology at the 
University Hospital Zurich with an ADVIA 2120 flow cytometer (Siemens, Eschborn, 
Germany). 
 
RNA extraction and quantitative real time PCR 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Switzerland). mRNA 
was reverse transcribed into cDNA using High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, USA). Bim (#Mm00437796_m1, Applied Biosystems), Bcl-2 
(#Mm00477631_m1*), TNF (#Mm99999068_m1) and IL1b (#Mm01336189_m1) 
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gene expression was determined with a TaqMan® Gene Expression Assay. Actin 
gene expression was measured as endogenous control (#4352341E; Applied 
Biosystems) and used for the calculation of relative mRNA expression by the Ct 
method. All samples were analyzed as triplicates. 
 
Analysis of apoptosis and flow cytometry 
Apoptosis was quantified by Terminal deoxynucleotidyl transferase dUTP nick end 
labelling (TUNEL) technology with the In Situ Cell Death Detection Kit 
(#11684795910, Roche, Mannheim, Germany) as described by the manufacturer.  
Numbers of living and apoptotic cells were determined by flow cytometry of annexin 
V- and PI-stained cells. Cells were resuspended in annexin V binding buffer as 
indicated by the manufacturer and stained with APC-conjugated annexin V (Enzo Life 
Science, Switzerland; diluted 1:40) and propidium iodide (PI; Sigma-Aldrich; final 
concentration 25 µg/ml). Annexin V- / PI- cells were considered alive, apoptotic cells 
displayed staining for annexin V but not for PI. 
Fluorescence was measured by flow cytometry using a BD FACSCanto II flow 
cytometer equipped with two lasers (excitation wave lengths: 488 nm and 633 nm). 
CD4 was stained with anti-mouse antibody from ImmunoTools (#22150043sp, 
1:1000). CD8 was stained with anti-mouse antibody from ImmunoTools 
(#22150083sp, 1:1000). Both primary antibodies were directly conjugated with FITC. 
 
Statistical analyses 
Real time PCR data were calculated from triplicates. Statistical analyses were 
performed using PASW statistics 18.0 (SPSS Inc., USA). Kruskal-Wallis non-
parametric analysis of variance and Bonferroni-corrected Mann-Whitney rank sum 
test were applied for animal experiments. Box plots express median with relative 
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quartiles, minimum and maximum. One-Way ANOVA and Tukey Post Hoc test were 
used for cell culture experiments. Bars represent mean values with whiskers 
displaying standard deviation. Differences were considered significant at p < 0.05 (*), 
highly significant at p < 0.01 (**) and very highly significant at p < 0.001 (***). 
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RESULTS 
 
ABT-737 is detected in blood and intestine following i.p. administration 
ABT-737 was applied in the Il10-/- model of spontaneous colitis. A calculated dose of 
50mg/kg/day was injected i.p. for 14 days. Control mice received a corresponding 
dose of vehicle solution over the same time-period. No treatment-related death or 
evidence of infection was observed in any of the animals. Water consumption was 
not reduced in mice treated with ABT-737 compared to controls. Peripheral blood, 
feces, intestinal epithelial cells (IEC) and whole colon tissue of mice were harvested 
(n = 4 each). By mass spectrometric (MS) quantification ABT-737 could be detected 
in the peripheral blood. Following 14 days of treatment, ABT-737 was localized in 
peripheral blood (0.47 ± 0.26 μg/μL), feces (9.44 ± 4.12 μg/g), IECs (6.07 ± 6.20 
μg/g) and whole colon tissue (3.67 ± 3.91 μg/g). This confirms that following i.p. 
administration ABT-737 indeed reaches the peripheral blood. MS quantification 
proved the presence of ABT-737 in whole colon tissue, its uptake into IEC and its 
accumulation in the feces. 
Additionally ABT-737 was applied in the murine model of acute DSS-induced colitis. 
50mg/kg/day was injected i.p. for nine days. By MS quantification ABT-737 could be 
detected in the peripheral blood (0.74 ± 0.37 μg/μL), feces (29.96 ± 21.17 μg/g), IECs 
(1.61 ± 2.90 μg/g) and whole colon tissue (7.17 ± 0.93 μg/g).  
 
ABT-737 induces a significant lymphopenia in mouse models of colitis 
Flow cytometry was performed to quantify viability of lymphocytes upon absorbed 
ABT-737 in Il10-/- mice. The relative number of live PBL was significantly reduced in 
Il10-/- upon ABT-737 compared to controls (45.4 ± 17.4 %, n = 8 vs. 82.4 ± 4.8 %, 
n = 8 respectively, p < 0.05, figure 1 A). Hematological analyses were performed in 
M. Hausmann et al. Apoptosis by ABT-737 in colitis is BIM dependent 
14 
the Il10-/- model of spontaneous colitis to determine whether the significant increase 
in number of apoptotic cells upon ABT-737 was associated with a shift in cell 
populations. The lymphocyte fraction was significantly reduced in Il10-/- mice after 14 
daily injections of ABT-737 when compared to vehicle-receiving controls (45.9 ± 16.1 
%, n = 8 vs. 67.2 ± 14.0 %, n = 8 respectively, p < 0.05, figure 1 B). The absolute 
number of lymphocytes was significantly reduced in Il10-/- upon ABT-737 compared 
to controls (0.53 ± 0.37 x 103 cells/μL, n = 8 vs. 1.83 ± 0.83 x 103 cells/μL, n = 8 
respectively, p < 0.05). In accordance the combined granulocyte and monocyte-
fraction was significantly increased in ABT-737-treated Il10-/- mice (49.3 ± 14.8 %, 
n = 8 vs. 24.6 ± 11.1 %, n = 8 respectively, p < 0.05, figure 1 C). The absolute 
number of the combined granulocyte and monocyte-fraction was reduced in Il10-/- 
upon ABT-737 compared to controls (0.54 ± 0.18 x 103 cells/μL, n = 8 vs. 0.88 ± 0.48 
x 103 cells/μL, n = 8 respectively) however not significantly different. In contrast 
erythrocyte counts were not affected (9.13 ± 0.83 x 1012 cells/L, n = 8 vs. 8.96 ± 0. 87 
x 1012 cells/μL, n = 8). As inhibition of BCL-2 by ABT-737 is mediated by displacing 
the pro-apoptotic factor BIM we also applied ABT-737 in Il10-/- x Bim-/-. Both the 
fraction of lymphocytes (78.8 ± 10.1 %, n = 5 vs. 81.2 ± 7.5 %, n = 4 respectively, 
figure 1 B) and of granulocytes and monocytes (10.9 ± 7.8 %, n = 5 vs. 12.8 ± 4.3 %, 
n = 4 respectively, figure 1 C) were unaltered upon ABT-737. The absolute number of 
lymphocytes remained unchanged in Il10-/- x Bim-/- upon ABT-737 compared to 
controls (6.16 ± 3.61 x 103 cells/μL, n = 5 vs. 5.47 ± 3.81 x 103 cells/μL, n = 5 
respectively) as well as the absolute number of the combined granulocyte and 
monocyte-fraction (0.90 ± 1.22 x 103 cells/μL, n = 5 vs. 1.08 ± 0.71 x 103 cells/μL, 
n = 5 respectively). PBL from colitic Il10-/- mice were analyzed by mass cytometry. 
TCRβ+, CD3+, CD4+ were analyzed for CD44 and CD62L expression (figure 1 D). 
The proportion of CD44+ CD62L+ central memory T cells was decreased upon ABT-
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737 (10.4 ± 7.4 %, n = 3) compared to vehicle-receiving controls (23.8 ± 8.1, n = 3). 
The proportion of TCRβ+, CD3+, CD8+, CD44+ CD62L- central memory T cells was 
decreased upon ABT-737 (17.9 ± 11.5 %, n = 3) compared to vehicle-receiving 
controls (34.2 ± 24.0, n = 3). 
Additionally hematological analyses for C57-BL/6J-Fue mice with a DSS-induced 
acute colitis confirmed significantly reduced absolute lymphocyte count upon ABT-
737 compared to controls (supplemental figure 1 A). ABT-737 levels in peripheral 
blood determined by MS were directly correlated to the removal of lymphocytes, as 
well as an increased relative number of granulocytes and monocytes (supplemental 
figure 1 C). The absolute number of the combined granulocyte and monocyte-fraction 
was reduced in mice suffering from DSS-induced colitis upon ABT-737 compared to 
controls (1.04 ± 0.68 x 103 cells/μL, n = 12 vs. 1.42 ± 1.04 x 103 cells/μL, n = 12 
respectively) however not significantly different. In flow cytometry CD8+ appeared to 
be diminished upon ABT-737 treatment, although the differences were not significant 
(7.8 ± 3.2 %, n = 10 vs. 10.7 ± 6.2 %, n = 12 respectively).  
 
The decrease in lymphocyte counts is accompanied by a reduction of pro-
inflammatory cytokines 
We determined whether the significant decrease of lymphocyte counts in Il10-/- mice 
was associated with a decrease in TNF and IL1b gene expression upon ABT-737 
treatment. The cytokine profile of Il10-/- mice was assessed in peripheral blood drawn 
from the tail vein on days 7 and 14. TNF gene expression was significantly 
decreased on day 14 in ABT-737-treated mice compared to vehicle-treated mice 
(82 ± 28, n = 8 vs. 241 ± 15, n = 8 respectively, figure 2 A). IL1b gene expression 
was also significantly decreased on day 14 in ABT-737-treated mice (49 ± 27, n = 8 
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vs. 276 ± 135, n = 8 respectively, figure 2 B). With regards to Il6 and Ifng mRNA 
expression, no significant changes were recorded.  
 
BIM is required for the protective effect of ABT-737  
Splenocytes from colitis Il10-/- mice were analyzed by flow cytometry after 14 daily 
injections of ABT-737. ABT-737 treatment was followed by a significant decrease in 
CD8+ splenocytes in Il10-/- mice compared to vehicle-receiving Il10-/- mice (15.9 ± 3.3 
%, n = 9 vs. 9.2 ± 2.5 %, n = 9 respectively, p < 0.05, figure 3 A and B). To elucidate 
ABT-737-dependent changes in apoptosis in the absence of BIM Bim-/- x Il10-/- mice 
were used. In contrast to the results obtained from Il10-/- mice there was no 
detectable difference in CD8+ splenocytes from Bim-/- x Il10-/- mice upon ABT-737 
(figure 3 A). This significant decrease in CD3+ CD8+ splenocytes in Il10-/- mice upon 
ABT-737 compared to vehicle-receiving Il10-/- mice (17.5 ± 1.1 %, n = 3 vs. 11.5 ± 1.9 
%, n = 3 respectively, p < 0.05, statistical analysis was performed using the Holm-
Sidak method, figure 3 C) was also confirmed by mass cytometry. 
 
Apoptosis of splenocytes is significantly increased upon ABT-737 treatment 
Increased apoptosis in peripheral blood was associated with a reduction of 
lymphocyte counts in ABT-737-treated mice. The level of cleavage of genomic DNA 
in spleen in the DSS-induced acute colitis model was analyzed. TUNEL assays 
revealed an increased apoptosis in mice treated for nine days with ABT-737 
(supplemental figure 2 A and B). Apoptosis-positive cells were detectable in the red 
pulp and to a lesser extent in the white pulp.  
Furthermore, ABT-737 treatment was followed by a significant reduction in spleen 
weight in C57-BL/6J-Fue mice suffering from DSS-induced acute colitis (0.10 ± 0.03 
g for vehicle-receiving mice as compared to 0.07 ± 0.02 g for ABT-737-receiving 
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mice, supplemental figure 2 C and D). This difference in spleen weight was not seen 
in colitic Bim-/- mice upon ABT-737 treatment. Irrespective of the treatment, spleen 
weight in Bim-/- was increased compared to C57-BL/6J-Fue mice, as previously 
described (supplemental figure 2 C). 
 
ABT-737 significantly increases apoptosis in Peyer’s patches  
The increased number of TUNEL+ cells in the peripheral blood and spleen indicated 
that the number of lymphocytes was reduced in ABT-737-treated mice. Additionally 
significantly increased cleavage of genomic DNA was found in Peyer’s patches in the 
Il10-/- model in both groups treated for five (supplemental figure 3 A) and 14 days 
(figure 4 A and B) with ABT-737. Next we isolated LPMNC from small bowel from 
Il10-/- treated for 14 days. Viable cells were identified by cisplatin staining followed by 
mass cytometry. A certain number of dead cells is certainly due to the isolation 
procedure, however, significantly increased number of dead cells was found in 
LPMNC isolated from small bowel in the Il10-/- model with ABT-737 compared to 
vehicle-treated mice (72.9 ± 3.1 %, n = 3 vs. 46.8 ± 12.2 %, n = 3 respectively, p < 
0.05, Holm-Sidak method, figure 4 C). A decrease in viable CD3+ CD4+ LPMNC in 
Il10-/- mice upon ABT-737 compared to vehicle-receiving Il10-/- mice (4.9 ± 3.8 %, 
n = 3 vs. 13.3 ± 6.4 %, n = 3 respectively, p < 0.05, figure 4 D) was confirmed by 
mass cytometry. Additionally a decrease in viable CD3+ CD8+ LPMNC upon ABT-737 
(3.6 ± 2.7 %, n = 3 vs. 11.2 ± 6.4 %, n = 3 respectively, p < 0.05, figure 4 D) was 
found. 
Although mice suffering from acute DSS-induced colitis do not develop ileitis TUNEL 
staining also revealed increased apoptosis in Peyer’s patches from mice treated for 
nine days with ABT-737 upon water (supplemental figure 4) or DSS (supplemental 
figure 5). TUNEL also revealed an increased apoptosis in the lamina propria of mice 
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treated for nine days with ABT-737 (supplemental figure 4 and 5). TUNEL+ cells 
appeared more frequently as clusters of more than four cells (supplemental figure 6). 
 
ABT-737 ameliorates spontaneous and acute colitis  
To determine the influence of ABT-737-dependent on mucosal inflammation and 
apoptosis both the Il10-/- model and the DSS-induced model were used. Macroscopic 
mucosal damage was assessed by mini-endoscopy. Il10-/- mice with a clearly visible 
rectal prolapse received 50mg/kg/day (n = 18) or vehicle (n = 14) over 14 days. Mice 
were sacrificed on day 14. Il10-/- mice receiving vehicle displayed an opaque mucosa 
and altered vascular pattern on day 14 (MEICS 6.9 ± 2.3, n = 14, figure 5 A). The 
thickening of the colon became more prominent, thin feces were discovered and the 
diseased regions frequently presented with mucosal bleeding. During treatment with 
ABT-737 inflammation was ameliorated. Compared to vehicle-receiving mice, Il10-/- 
mice treated with ABT-737 had a transparent mucosa with a regular vascular pattern. 
Solid feces were visible (MEICS 3.6 ± 1.7, n = 18, figure 5 B). No differences in 
MEICS were determined in Il10-/- x Bim-/- upon ABT-737 (figure 5 A and B).  
Additionally mice upon acute colitis receiving vehicle displayed an opaque mucosa 
and altered vascular pattern on day 9 (MEICS 4.3 ± 1.8, n = 14, supplemental figure 
7). Colon became thickened, extensive amounts of feces were discovered and the 
diseased regions frequently presented with mucosal bleeding. During treatment with 
ABT-737 signs of an ameliorated inflammation were found. Mice suffering from DSS-
induced acute colitis but treated with ABT-737 had a transparent mucosa with a 
regular vascular pattern. Solid feces were visible (MEICS 1.4 ± 0.9, n = 13, 
supplemental figure 7). In contrast, no difference in MEICS was determined in Bim-/- 
mice treated with ABT-737 (supplemental figure 7). In summary ABT-737 positively 
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altered the colonic mucosa at a macroscopic level in both the Il10-/- model of 
spontaneous colitis and DSS-induced acute colitis. 
Colon length was determined in both spontaneous colitis and DSS-induced acute 
colitis models. In Il10-/- mice ABT-737 treatment prevented the shortening in colon 
length significantly (8.18 ± 0.27 cm vs. 7.65 ± 0.38 cm, respectively, figure 6 A). The 
histological score of Il10-/- mice treated with ABT-737 was significantly lower as in 
untreated mice (figure 6 B). ABT-737-treated Il10-/- mice had less lymphocyte influx in 
the thickened lamina propria (figure 6 C). Compared to vehicle-receiving mice, Il10-/- 
mice treated with ABT-737 showed increased body weight (figure 6 D) however not 
significantly different. 
In C57-BL/6J-Fue mice, induction of DSS-induced acute colitis was followed by a 
significant reduction in colon length (supplemental figure 8 A). ABT-737 treatment 
prevented the shortening in colon length significantly in DSS-induced colitis 
(7.44 ± 0.51 cm, n = 18 vs. 6.35 ± 0.57 cm, n = 18, p < 0.001, respectively, 
supplemental figure 8 A). The number of lymphocytes in colonic mucosa was 
determined and immunohistochemistry applying anti-CD3 antibody was performed. 
CD3+ cells in the acquired images were appropriately marked and quantified by an 
investigator blinded to the experiment setup. Immunohistochemistry revealed a 
decreased number of CD3+ in the colonic lamina propria of mice treated for nine days 
with ABT- (49.5 ± 39.5 cells/hpf, n = 16 hpfs and 70.1 ± 30.4 cells/hpf, n = 14 hpfs, 
respectively, supplemental figure 8 B).  
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CD4+CD62L+ are susceptible for priming with ABT-737 but Bcl-2 increases 
during ongoing inflammation 
We assessed ABT-737-dependent priming for apoptosis in lymphocyte sub-
populations. Il10-/- with a clearly visible rectal prolapse received either a dose of 
50mg/kg/day ABT-737 (n = 5) or vehicle (n = 5) for 14 days as in vivo pre-treatment. 
CD4+CD62L+ were isolated from the splenocytes and incubated for 12h with ABT-
737 or vehicle. Following ABT-737 in vivo pre-treatment CD4+CD62L+ cells became 
significantly more susceptible to apoptosis initiated by ABT-737 compared to vehicle 
controls (figure 7 A). According contour plots for are shown in supplemental figure 9. 
Furthermore, BIM and BCL-2 gene expression in CD4+CD62L+ and CD4+CD62L- 
cells after pre-treatment with either ABT-737 or vehicle was determined. The BIM / 
BCL-2 ratio was significantly decreased on day 14 in CD4+CD62L+ from ABT-737-
treated mice compared to vehicle treated mice (26 ± 8, n = 5 vs. 87 ± 13, n = 5 
respectively, figure 7 B). In vivo pre-treatment with ABT-737 lowered the BIM / BCL-2 
ratio in CD4+CD62L+. As the BIM / BCL-2 ratio was significantly decreased on day 14 
in CD4+CD62L+ from ABT-737-treated mice BCL-2 and BCL-XL gene expression in 
CD4+CD62L+ cells in relation to age and treatment was determined. CD4+CD62L+ 
from Il10-/- 8 weeks of age (n = 5) were compared to 12 weeks old mice with (n = 5) 
and without ABT-737 treatment (n = 5). 8 week-old mice without visible rectal 
prolapse were compared with 12 week-old mice with either a visible or a developing 
rectal prolapse. BCL-2 gene expression was significantly increased in older mice 
compared to younger mice. BCL-2 was also significantly increased upon ABT-737 
compared to vehicle control (figure 7 C).   
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Apoptosis stimulating effect is decreased upon ABT-737 long-term treatment  
Long term treatment with ABT-737 in Il10-/- mice was performed. Il10-/-, at 8 weeks of 
age, with no signs of rectal prolapse, received either 50mg/kg ABT-737 every three 
days (n = 10) or vehicle (n = 10) over a period of 56 days. Treatment was applied i.p. 
Long term treatment with ABT-737-induced depigmentation of the abdominal skin, 
whereas the head, chest and back were not affected (supplemental figure 10). 
Il10-/- were sacrificed on day 56. 7 mice upon ABT-737 and 8 vehicle-treated mice 
developed a clearly visible rectal prolapse during the experiment. Macroscopic 
mucosal damage was assessed by mini-endoscopy and colonoscopy score on day 
14 and on day 55. On day 55 Il10-/- mice from both groups displayed an opaque 
mucosa and altered vascular pattern (figure 8 A). The thickening of the colon became 
more prominent, thin feces were discovered and the diseased regions frequently 
presented with mucosal bleeding. (MEICS 10.0 ± 2.5, n = 5 for mice devoid of ABT-
737 compared to 11.1 ± 2.9, n = 5 for mice upon ABT-737, figure 8 B).  
The cytokine profile in peripheral blood was assessed on days 0, 14, 28, 42 and 56 
without further pre-stimulation of lymphocytes at mRNA level (figure 8 C). In support 
of data from short time-frame experiments mentioned above, TNF gene expression 
was significantly decreased on day 14 in ABT-737-treated mice compared to vehicle-
treated mice. No significant changes were recorded between treatment with ABT-737 
and vehicle on day 56. 
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DISCUSSION 
 
As dysregulated apoptosis of activated lymphocytes driven by increased anti-
apoptotic BCL-2 and BCL-XL contributes to the pathogenesis of IBD (3, 4, 6, 7, 32) 
we analyzed the potential of the priming agent ABT-737 to limit the persistence of 
lymphocytes in mouse models of colitis. 
In the present study, we applied pro-apoptotic ABT-737 in both the murine model of 
acute DSS-induced colitis and the Il10-/- model of spontaneous colitis. Following i.p. 
administration ABT-737 was detected in peripheral blood, colon tissue and IEC. We 
determined ABT-737 accumulation in the feces. ABT-737 treatment lead to 
lymphopenia in mice demonstrated by the reduced lymphocyte and thrombocyte 
counts as well as the increased fraction of combined granulocytes and monocytes 
compared to controls. PBL were cleared in a dose-dependent manner upon ABT-737 
and proportions of CD8+ appeared to be diminished. Increased apoptosis upon ABT-
737 was determined in PBL, splenocytes and Peyer’s patches and was accompanied 
by a decrease in TNF and IL1b gene expression compared to vehicle-control. CD4+ 
CD44+ CD62L+ central memory T cells were decreased in PBL upon ABT-737 
compared to vehicle-receiving controls. CD8+, CD44+ CD62L- central memory T cells 
were also decreased upon ABT-737. Naïve T cells require both MCL-1 and BCL-2 for 
survival (Ivan Dzhagalov et al.). In our own experiments CD4+ naïve T cells are 
hardly affected by ABT-737 which is not inhibiting MCL-1. This may protect T cell 
sub-populations from initiation of apoptosis and contribute to a low BIM / BCL-2 ratio 
in remaining cells. ABT-737 positively alters the colonic mucosa at both macroscopic 
and microscopic level, while also ameliorating intestinal inflammation in models of 
colitis as shown by MEICS, histological score and colon length. Inactivation of BCL-2 
is key to the ability of BIM to induce apoptosis. BIM can also directly bind to pro-
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apoptotic BAX and BAK in order to initiate apoptosis (33). Other BH3-only proteins 
such as BMF, BAD, NOXA and PUMA are considered to act as sensitizers which 
bind the pro-survival BCL-2 protein and thereby displace BIM from BCL-2 to promote 
cell death (34). As inhibition of BCL-2 by ABT-737 is mediated by BIM we also 
applied ABT-737 to both Il10-/- x Bim-/- upon spontaneous colitis and Bim-/- upon DSS-
induced acute colitis and confirmatively mice were found to be relatively resistant to 
the lymphocyte apoptosis upon ABT-737 administration. In our own experiments we 
could also show that following 14 days of ABT-737 pre-treatment in vivo, gut-homing 
CD4+CD62L+ cells became more susceptible to apoptosis compared to vehicle 
controls. BIM / BCL-2 balance is critical for maintaining T cell homeostasis (9). 
However, the BIM / BCL-2 ratio was decreased with age and over the course of 
treatment in our own experimental setup. Thus long-term treatment over a period of 
56 days resulted in adapted TNF levels and macroscopic mucosal damage. 
 
ABT-737 affects various transformed cells, while exhibiting minimal toxicity toward 
normal cells. Navitoclax, the orally administered form of ABT-737, has been applied 
in chronic lymphocytic leukemia (CLL). CLL is characterized by the accumulation of 
lymphocytes, typically of B-cell origin, in the blood, lymph nodes and spleen. In a 
phase I study of 26 patients, nine achieved a partial response and seven maintained 
stable disease for more than 6 months (35). Furthermore, the expression of Bim, and 
the extent of its association with Bcl-2, correlates with in vivo ABT-737-sensitivity in 
CLL (27). Navitoclax has also been successfully tested in small cell lung cancer 
xenograft models. Although Navitoclax exhibited an important range of antitumor 
activity, leading to complete tumor regression in several models (36), Bcl-2 targeting 
by navitoclax showed limited single-agent activity against advanced and recurrent 
small cell lung cancer in a phase II study (37). 
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Studies observing ABT-737 in inflammatory conditions characterized by the 
uncontrolled proliferation of lymphocytes yielded results which corroborated our own 
findings. ABT-737 was efficacious in reducing accumulated lymphocytes associated 
with tissue and organ damage in other animal models of autoimmunity. Collagen-
induced arthritis in DBA/J mice is a well-established rodent model for rheumatoid 
arthritis, which is clinically characterized by paw swelling leading to ankylosis. 
Treatment with ABT-737 and dexamethasone significantly reduced the mean arthritic 
score and paw swelling compared with the vehicle-treated group (24). ABT-737 
treatment was associated with lymphocyte and platelet depletion. In parallel ABT-737 
was applied in a murine model of delayed-type hypersensitivity (DTH) in C57BL/6 
mice. The DTH test is used to determine whether a prior exposure to a specific 
antigen has occurred. This reaction has been shown to be dependent on CD4+ and 
CD8+ memory T cells. Treatment with ABT-737 and dexamethasone showed a 
similar reduction in paw swelling compared to the vehicle-treated group (24). ABT-
737 was also applied in a murine model of Ifng-induced lupus nephritis. Treatment 
with ABT-737 prolonged survival and reduced glomerulonephritis to a similar extent 
to that observed with mycophenolate mofetil (24). In animal models of systemic lupus 
erythematosus a decrease in lymphocyte apoptosis is clearly associated with more 
severe disease pathogenesis. Both Bcl-2-transgenic mice (38) and Bim-deficient 
mice (39) show evidence of systemic lupus erythematosus-like clinical symptoms 
caused by prolonged survival of lymphocytes. In patients with lupus, elevated Bcl-2 
expression in lymphocytes has been reported (40). 
 
The regulative function of ABT-737 on uncontrolled proliferation of lymphocytes could 
be also confirmed with a different approach. ABT-737 suppresses allogeneic T- and 
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B-cell responses after skin transplantation (41). In vitro, ABT-737 prevented 
allogeneic T cell activation, proliferation, and cytotoxicity by inducing apoptosis. The 
physiological functions of the remaining viable T cells were not impaired. In vivo, 
ABT-737 was highly selective for lymphoid cells and inhibited allogeneic T- and B-cell 
responses after skin transplantation. 
 
In recent years the importance of expansion and contraction of activated 
lymphocytes by apoptosis has been extensively discussed. Failure in the apoptotic 
mechanism of lymphocyte control can lead to the development of autoimmunity. 
Inducing the apoptosis of lymphocytes may provide the basis for a new therapeutic 
strategy in CD patients. Furthermore, investigating the imbalance between pro-and 
anti-apoptotic proteins could help predict clinical relapse upon standard medical 
therapy. Ultimately, this knowledge could lead to the development of new therapeutic 
options for the treatment of IBD, by focusing on controlling the abnormally large 
population of activated cells and thereby restoring a physiological turnover of 
lymphocytes and homeostasis. 
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Titles and legends to figures 
 
Figure 1 Cell death upon ABT-737 is selective for PBL  
(A - D) Il10-/- and Il10-/- x Bim-/- mice in the model of spontaneous colitis. (A) Flow 
cytometry revealed an increased number of PI+ cells in PBL upon ABT-737 
treatment. Mann-Whitney rank sum test. Treatment with ABT-737 (B) significantly 
decreased the number of lymphocytes and (C) significantly increased number of 
granulocytes compared to vehicle. Statistical analysis was performed using ANOVA 
and All Pairwise Multiple Comparison Procedures (Bonferroni t-test), p < 0.05 (*). (D) 
Mass cytometry revealed a decreased proportion of CD44+ CD62L+ central memory 
T cells upon ABT-737 compared to vehicle.  
 
Figure 2: During spontaneous colitis in Il10-/- pro-inflammatory cytokines were 
significantly decreased upon ABT-737-treatment compared to vehicle-receiving 
controls. mRNA expression levels determined by qPCR from (A) TNF and (B) IL1b. 
Statistical analysis was performed using the Mann-Whitney rank sum test, p < 0.05 
(*). 
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Figure 3: Increased apoptosis in the spleen upon ABT-737 treatment.  
(A -C) Il10-/- mice suffering from spontaneous colitis. (A) Decreased number of CD8+ 
splenocytes in Il10-/- upon ABT-737 compared to vehicle determined by flow 
cytometry. Number of CD4+ and CD8+ splenocytes in Bim-/- x Il10-/- remained 
unchanged upon ABT-737. Statistical analysis was performed using the Mann-
Whitney rank sum test, p < 0.05 (*). (B) Decreased number of CD8+ splenocytes in 
Il10-/- upon ABT-737 compared to vehicle determined by flow cytometry. (C) Mass 
cytometric analysis of TCRβ+ splenocytes revealed a significantly decreased 
proportion of CD3+ CD8+ T cells upon ABT-737 compared to vehicle. Statistical 
analysis was performed using the Holm-Sidak method, p < 0.05 (*). 
 
Figure 4: Increased number of TUNEL+ cells in Peyer’s patches of the small 
bowel upon ABT-737. (A) Il10-/- mice were sacrificed at day 14. Original 
magnification × 630. Statistical analysis was performed using the Mann-Whitney rank 
sum test, p < 0.05 (*). (B) The number of cells was calculated from four high power 
fields for each mouse. (C) Mass cytometric analysis of LPMNC revealed a 
significantly decrease in dead cells upon ABT-737 compared to vehicle. Statistical 
analysis was performed using the Holm-Sidak method, p < 0.05 (*). (D) Mass 
cytometric analysis of LPMNC revealed a decrease in both CD3+ CD4+ and CD3+ 
CD8+ T cells upon ABT-737 compared to vehicle.  
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Figure 5: Mice suffering from colitis develop an ameliorated intestinal 
inflammation upon ABT-737-treatment as compared to vehicle-receiving mice.  
(A and B) Il10-/- mice suffering from spontaneous colitis. (A) Representative images 
demonstrate colonoscopy pictures derived from ABT-737- and vehicle-treated mice. 
(B) Statistical analysis of colonoscopy score (MEICS). Normality test was passed and 
statistical analysis was performed using One Way ANOVA (Bonferroni t-test). 
Colonoscopy was performed on the day prior to sacrificing the animals. Box plots 
express median, 95/5 % percentiles and outliers, p <  0.05 (*). 
 
Figure 6: ABT-737 treatment was followed by a significant increase of the colon 
length.  
(A - D) Il10-/- mice suffering from spontaneous colitis. (A) In Il10-/- mice ABT-737 
treatment was followed by a significant increase in colon length. Statistical analysis 
was performed using the Mann-Whitney rank sum test. (B) Histological score was 
significantly decreased upon ABT-737 treatment. Statistical analysis was performed 
using the Mann-Whitney rank sum test. Box plots express median. (C) H&E staining 
of distal colon. Images representative for n = eight each, p < 0.05 (*),p <  0.001 (***). 
(D) Body weight curve. 
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Figure 7: Significantly increased apoptosis in CD4+CD62L+ from Il10-/- mice 
upon ABT-737 pre-treatment as compared to vehicle. (A) CD4+CD62L+ cells were 
isolated from Il10-/- mice treated for 14 days with ABT-737 or vehicle in vivo. 
CD4+CD62L+ cells were stimulated in vitro with ABT-737 or vehicle in a dose 
dependent manner. Following ABT-737 pre-treatment, cells became significantly 
more susceptible to the initiation of apoptosis as determined by flow cytometry. (B) 
BIM / BCL-2 ratio was significantly decreased in CD4+CD62L+ from ABT-737-treated 
mice compared to vehicle treated mice. (C) BCL-2 and BCL-xL qPCR of splenocytes 
isolated from Il10-/-. Gene expression was increased in a time-dependent manner and 
upon ABT-737-treatment compared to vehicle-receiving controls. Statistical analysis 
was performed using the Mann-Whitney rank sum test, p < 0.05 (*). 
 
Figure 8: During long-term treatment Il10-/- mice develop intestinal inflammation 
despite ABT-737 application (50mg/kg/three days over 14 and 56 days), 
similarly to vehicle-receiving mice. (A) Representative images demonstrate 
colonoscopy pictures derived from ABT-737- and vehicle-treated Il10-/- mice. (B) 
Statistical analysis of colonoscopy score (MEICS). Colonoscopy was performed on 
days 14 and 56, (one day prior to sacrificing the animals). Box plots express median, 
95/5 % percentiles and outliers. (C) The cytokine profile of peripheral blood 
lymphocytes isolated from Il10-/- is altered in a time-dependent manner upon ABT-
737-treatment compared to vehicle controls. TNF mRNA expression levels 
determined by qPCR. Statistical analysis was performed using the Mann-Whitney 
rank sum test, p < 0.05 (*). 
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RESULTS 
ABT-737 induces a significant lymphopenia in mouse models of colitis 
Additionally hematological analyses for C57-BL/6J-Fue mice with a DSS-induced 
acute colitis were performed. After nine daily injections of ABT-737 a significantly 
reduced lymphocyte count was shown compared to controls (1.48 ± 0.98 x 103 
cells/μL, n = 10 vs. 3.49 ± 2.60 x 103 cells/μL, n = 13 respectively, p < 0.05, 
supplemental figure 1A). Similarly, ABT-737 mice had a significant reduction in 
thrombocytes (485 ± 141 x 103 platelets/μL, n = 10 vs. 837 ± 233 x 103 platelets/μL, 
n = 13, p < 0.05). Accordingly a significantly increased fraction of combined 
granulocytes and monocytes in ABT-737 mice was found (34.3 ± 7.4 %, n = 10 vs. 
20.8 ± 10.1 %, n = 13, p < 0.05, supplemental figure 1B). ABT-737 levels in 
peripheral blood determined by MS were directly correlated to the removal of 
lymphocytes, as well as the increased fractions of granulocytes and monocytes 
(supplemental figure 1C). Animals with high levels of ABT-737 displayed high efficacy 
in lymphocyte removal, while animals with minimal levels of ABT-737 had almost 
normal lymphocyte counts. The fraction of combined granulocytes and monocytes 
was inversely proportional to ABT-737 levels (supplemental figure 1C). In contrast 
erythrocytes were not affected upon ABT-737 treatment (8.57 ± 1.32 x 1012 cells/L, 
n = 10 vs. 8.07 ± 1. 09 x 1012 cells/μL, n = 13). In Bim-/- mice lymphocyte counts and 
fraction of combined granulocytes and monocytes were not significantly different 
upon ABT-737 (supplemental figure 1A and B). Flow cytometry of peripheral blood 
cells indicated that proportions of CD4+ remained unchanged upon DSS-induced 
acute colitis and after nine daily injections of ABT-737 in C57-BL/6J-Fue mice 
(16.1 ± 7.9 %, n = 11 vs. vehicle-receiving controls: 18.4 ± 13.4 %, n = 12 
respectively). CD8+ appeared to be diminished upon ABT-737 treatment, although 
the differences were not significant (7.8 ± 3.2 %, n = 10 vs. 10.7 ± 6.2 %, n = 12 
respectively). The fraction of autoreactive CD4+ lymphocytes positive for TCR Vβ8 
(46.8 ± 6.7 %, n = 4 vs. 46.2 ± 10.9 %, n = 5 respectively) and CD8+ lymphocytes 
positive for TCR VB8 (45.3 ± 10.2 %, n = 3 vs. 39.0 ± 17.7 %, n = 5 respectively) 
remained unchanged.  
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Supplemetal figure 1 Cell death upon ABT-737 is selective for PBL  
(A - C) C57-BL/6J-Fue and Bim-/- mice upon DSS-induced acute colitis (vehicle = 
white, ABT-737 = grey). Hematological analyses revealed (A) a significantly 
decreased number of lymphocytes and (B) a significantly increased number of 
granulocytes upon ABT-737 compared to vehicle controls. ANOVA and Kruskal-
Wallis One Way Analysis of Variance on Ranks (Dunn's Method). (C) ABT-737 levels 
were directly related to the removal of lymphocytes.  
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Supplemental figure 2: Increased apoptosis in the spleen upon ABT-737 
treatment.  
(A - D) C57BL/6 mice with DSS-induced acute colitis. (A) H&E staining and TUNEL+ 
cells (red) in spleen upon ABT-737 treatment. Mice treated with ABT-737 or vehicle 
received either (A) water or (B) DSS. Mice were sacrificed at day nine. Treatment 
with ABT-737 was followed by an increase in TUNEL+ cells in both red pulp and white 
pulp. Images representative for five mice each. Original magnification as indicated. 
(C) Spleen weights in DSS-induced acute colitis in C57BL/6 mice. C57BL/6 mice 
were treated with ABT-737 or vehicle and received either water or DSS. Treatment 
with ABT-737 was followed by a decrease in spleen weight. Induction of colitis was 
followed by a significant increase of the spleen, shown to be significantly decreased 
upon ABT-737. Statistical analysis was performed using the Kruskal-Wallis one way 
ANOVA, all pairwise multiple comparison procedures (Dunn's method), p <  0.05 (*). 
(D) Spleen of a mouse which received vehicle (left) or ABT-737 (right) upon DSS. 
Images representative for fourteen and twenty mice, respectively. 
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Supplemental figure 3: 
 
 
 
 
 
 
 
 
 
 
 
Supplemental figure 3: Increased number of TUNEL+ cells in Peyer’s patches of 
the small bowel upon ABT-737 compared to vehicle treatment in the IL-10-/- 
model of spontaneous colitis. Mice upon ABT-737 or vehicle were sacrificed at day 
five. Original magnification × 630. Statistical analysis was performed using the Mann-
Whitney rank sum test, p < 0.05 (*). The number of cells was calculated from four 
high power fields for each mouse. 
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Supplemental figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental figure 4: Increased number of TUNEL+ cells in Peyer’s patches of 
the small bowel upon ABT-737. Water control mice upon vehicle or ABT-737. Mice 
were sacrificed at day nine. Treatment with ABT-737 was followed by an increase in 
TUNEL+ cells in Peyer’s patches of the small bowel. Images representative for five 
mice each. Original magnification as indicated. 
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Supplemental figure 5: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental figure 5: Increased number of TUNEL+ cells in Peyer’s patches of 
the small bowel upon ABT-737. Mice upon DSS were sacrificed at day nine. 
Treatment with ABT-737 was followed by an increase in TUNEL+ cells in Peyer’s 
patches. Images representative for five mice each. Original magnification as 
indicated.   
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Supplemental figure 6: 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental figure 6: Increased number of TUNEL+ cells in Peyer’s patches of 
the small bowel upon ABT-737 treatment in DSS-induced acute colitis in 
C57BL/6 mice. TUNEL+ cells frequently appeared as clusters of more than four cells 
in mice treated with ABT-737 compared to vehicle. Original magnification as 
indicated. 
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B 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental figure 7: Mice suffering from colitis develop an ameliorated 
intestinal inflammation upon ABT-737-treatment as compared to vehicle-
receiving mice. (A and B) C57BL/6 mice with DSS-induced acute colitis. (A) 
Representative images demonstrate colonoscopy pictures derived from ABT-737- 
and vehicle-treated mice. (B) Statistical analysis of colonoscopy score (MEICS). 
Statistical analysis was performed using the Kruskal-Wallis One Way Analysis of 
Variance on Ranks (Dunn's Method).  
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Supplemental figure 8 
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Supplemental figure 8: ABT-737 treatment was followed by a significant increase 
of the colon length. (A and B) Acute DSS- induced colitis in C57BL/6 mice. (A) Mice 
upon ABT-737 or vehicle received either water or DSS. Statistical analysis was 
performed using the one way ANOVA, all pairwise multiple comparison procedures 
(Bonferroni). (B) ABT-737-treatment was followed by a decrease in CD3+ in colonic 
lamina propria. Original magnification x 10.  
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Supplemental figure 9 
 
 
 
 
 
 
 
 
 
 
 
Supplemental figure 9: ABT-737 treatment was followed by a significant increase 
of apoptosis in CD4+CD62L+ in a dose-dependent manner. Contour plots. 
Following ABT-737 in vivo pre-treatment CD4+CD62L+ cells became susceptible to 
apoptosis initiated by ABT-737 compared to vehicle controls (ABT-737 concentration 
as indicated). Living cells, annexin V- / PI-; apoptotic cells, annexin V+ / PI-. 
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Supplemental figure 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental figure 10: Depigmentation of the abdominal fur. Hair depigmentation 
after 56 days of long term treatment of IL-10-/- with ABT-737 (50 mg/kg/three days).  
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